PMID- 12635130
OWN - NLM
STAT- MEDLINE
DCOM- 20030606
LR  - 20151119
IS  - 0022-3417 (Print)
IS  - 0022-3417 (Linking)
VI  - 199
IP  - 4
DP  - 2003 Apr
TI  - The clinical evaluation of HER-2 status: which test to use?
PG  - 411-7
AB  - Accurate determination of the status of the type I receptor tyrosine kinase HER-2 
      in breast carcinomas provides significant insight into patient prognosis and may 
      also inform selection of chemotherapeutic and hormonal treatments. At present, 
      however, the single most important application of HER-2 testing is in the 
      selection of patients for treatment with targeted therapies such as Herceptin. 
      Although, based on current literature, fluorescence in situ hybridization (FISH) 
      detection of HER-2 gene amplification may provide more accurate information in 
      this context, this method is not yet widely available. Therefore, screening by 
      immunohistochemistry (IHC) for HER-2 protein, backed by rigorous quality controls 
      and FISH testing of equivocal cases with intermediate staining intensity, remains 
      the current practice. In laboratories with highly standardized testing and 
      quality assurance procedures, this protocol appears highly effective. 
      Improvements in fixation procedures, standardization of antibodies, and use of 
      automated image analysis may all increase the precision of IHC testing. However, 
      on the basis of current data, there is a case to be made for the wider 
      implementation of FISH testing to determine HER-2 status in breast cancer.
CI  - Copyright 2003 John Wiley & Sons, Ltd.
FAU - Bartlett, John
AU  - Bartlett J
AD  - University Department of Surgery, Glasgow Royal Infirmary, Glasgow, UK. 
      j.m.bartlett@clinmed.gla.ac.uk
FAU - Mallon, Elizabeth
AU  - Mallon E
FAU - Cooke, Tim
AU  - Cooke T
LA  - eng
PT  - Comment
PT  - Journal Article
PT  - Review
PL  - England
TA  - J Pathol
JT  - The Journal of pathology
JID - 0204634
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Neoplasm Proteins)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
CON - J Pathol. 2003 Apr;199(4):418-23. PMID: 12635131
MH  - Biomarkers, Tumor/*analysis
MH  - Breast Neoplasms/*chemistry
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Neoplasm Proteins/analysis
MH  - Observer Variation
MH  - Quality Control
MH  - Receptor, ErbB-2/*analysis
MH  - Reproducibility of Results
RF  - 72
EDAT- 2003/03/14 04:00
MHDA- 2003/06/07 05:00
CRDT- 2003/03/14 04:00
PHST- 2003/03/14 04:00 [pubmed]
PHST- 2003/06/07 05:00 [medline]
PHST- 2003/03/14 04:00 [entrez]
AID - 10.1002/path.1354 [doi]
PST - ppublish
SO  - J Pathol. 2003 Apr;199(4):411-7. doi: 10.1002/path.1354.